Literature DB >> 17938262

Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.

Eun-Ryeong Hahm1, Shivendra V Singh.   

Abstract

The present study was undertaken to gain insights into the mechanism of cell cycle arrest caused by honokiol, a constituent of oriental herb Magnolia officinalis. The honokiol treatment decreased the viability of PC-3 and LNCaP human prostate cancer cells in a concentration- and time-dependent manner, which correlated with G0-G1 phase cell cycle arrest. The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein. The honokiol-treated PC-3 and LNCaP cells exhibited a marked decrease in the levels of total and phosphorylated retinoblastoma protein (Rb), which correlated with the suppression of transcriptional activity of E2F1. Exposure of PC-3 and LNCaP cells to honokiol resulted in the induction of p21 (PC-3 and LNCaP) and p53 protein expression (LNCaP). However, small interfering RNA (siRNA)-mediated knockdown of either p21 (PC-3 and LNCaP) or p53 (LNCaP) protein failed to confer any protection against honokiol-induced cell cycle arrest. The honokiol treatment caused the generation of reactive oxygen species (ROS), and the cell cycle arrest caused by honokiol was partially but significantly attenuated in the presence of antioxidant N-acetylcysteine. In conclusion, the present study reveals that the honokiol-mediated G0-G1 phase cell cycle arrest in human prostate cancer cells is associated with the suppression of protein level/phosphorylation of Rb leading to inhibition of transcriptional activity of E2F1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938262     DOI: 10.1158/1535-7163.MCT-07-0217

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  43 in total

1.  In vitro growth inhibition of human cancer cells by novel honokiol analogs.

Authors:  Jyh Ming Lin; A S Prakasha Gowda; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2012-04-03       Impact factor: 3.641

2.  Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells.

Authors:  Dhanir Tailor; Eun-Ryeong Hahm; Raosaheb K Kale; Shivendra V Singh; Rana P Singh
Journal:  Mitochondrion       Date:  2013-10-29       Impact factor: 4.160

3.  Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles.

Authors:  MaLing Gou; XiuLing Zheng; Ke Men; Juan Zhang; BiLan Wang; Lei Lv; XiuHong Wang; YinLan Zhao; Feng Luo; LiJuan Chen; Xia Zhao; YuQuan Wei; ZhiYong Qian
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

4.  Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Mandip Singh
Journal:  Colloids Surf B Biointerfaces       Date:  2017-01-23       Impact factor: 5.268

Review 5.  Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents.

Authors:  Mélanie Poivre; Pierre Duez
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

6.  Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Kozue Sakao; Shivendra V Singh
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

7.  Honokiol inhibits melanoma stem cells by targeting notch signaling.

Authors:  Gaurav Kaushik; Anand Venugopal; Prabhu Ramamoorthy; David Standing; Dharmalingam Subramaniam; Shahid Umar; Roy A Jensen; Shrikant Anant; Joshua M V Mammen
Journal:  Mol Carcinog       Date:  2014-12-09       Impact factor: 4.784

8.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

9.  Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases.

Authors:  Sunga Choi; Tae Woong Kim; Shivendra V Singh
Journal:  Pharm Res       Date:  2009-07-23       Impact factor: 4.200

10.  c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Krishna Beer Singh; Shivendra V Singh
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.